Post-Stroke Osteopathy

Sponsor
VASCage GmbH (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04845269
Collaborator
Medical University Innsbruck (Other)
127
1
26
4.9

Study Details

Study Description

Brief Summary

The sudden biomechanical inactivation, direct neuro-humoral effects and sustained systemic stress reaction, which commonly occur after stroke or TIA, all may be of relevance in triggering alterations in bone metabolism and remodelling of bone microstructure.

The objectives of this observational pilot study are to characterize falls and fractures and their circumstances (sex and age specific incidence, time course, risk conditions, localization) in ischemic stroke patients, study changes in the bone microstructure after ischemic stroke supported by high-resolution peripheral quantitative Computer Tomography, unravel a molecular mechanisms underlying the increased fracture risk (focus on Wnt-signaling and ß-adrenergic projection), establish risk factors to estimate the risk of falls based on information from gait analysis as well as construct deep learning algorithms to identify bone microstructure parameters for predicting fractures.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    127 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Post-Stroke Osteopathy: Characterization of Fractures and Changes in the Bone Microstructure After Ischemic Stroke or TIA
    Actual Study Start Date :
    Mar 31, 2021
    Anticipated Primary Completion Date :
    May 31, 2023
    Anticipated Study Completion Date :
    May 31, 2023

    Outcome Measures

    Primary Outcome Measures

    1. Number of patients with and without fractures [12 months]

    Other Outcome Measures

    1. Changes in imaging bone structure between the baseline and follow-up in all extremities as measured by quantitative CT imaging [12 months]

    2. Number and circumstances (housing situation, concomitant medication, level of immobility,...) of falls between baseline and one-year follow-up [12 months]

      Due to the observational nature of the study, these outcome parameters will be published with descriptive statistics

    3. Change in blood bone biomarkers (as mentioned before) between baseline and follow-up [12 months]

      CTX1 und CTX 2, Osteocalcin, TRAP5b, Bone Alkaline Phosphatase, Sclerostin, Periostin, RANKL-OPG-Ratio

    4. Circumstances (housing situation, concomitant medication, level of immobility,...) of fractures during the twelve-month follow up [12 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    60 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Inclusion in the STROKE-CARD Registry Study

    • Modified Rankin Scale (mRS) < 5

    • Provision of signed and dated informed consent form

    • Willingness to comply with all study procedures and ability to participate in the study over the complete study duration

    Exclusion Criteria:
    • Persistent motor deficit before the onset event

    • Not able to walk without walking aid or not able to put the full bodyweight on either leg before the onset event

    • Medical history of stroke

    • Premedication with Corticosteroids for more than 6 Weeks or Pioglitazone or Bisphosphonate within the last 12 months

    • Limb amputation

    • BMI < 18,5 kg/m2 or > 35 kg/m2

    • Present or previous fracture in the distal Radius or Tibia interfering with HR-pQCT

    • Movement disorder interfering with HR-pQCT imaging

    • Women of childbearing potential

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Medical University of Innsbruck, Department of Neurology Innsbruck Austria 6020

    Sponsors and Collaborators

    • VASCage GmbH
    • Medical University Innsbruck

    Investigators

    • Principal Investigator: Michael Knoflach, Assoz.Prof. Priv.-Doz. Dr., Medical University of Innsbruck, Department of Neurology

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    VASCage GmbH
    ClinicalTrials.gov Identifier:
    NCT04845269
    Other Study ID Numbers:
    • VASC-E3-2020-06
    First Posted:
    Apr 14, 2021
    Last Update Posted:
    Jun 24, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by VASCage GmbH
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 24, 2022